LLY

965.93

+4.72%↑

JNJ

187.89

+0.86%↑

UNH

321.52

-0.8%↓

NVS

127.05

+0.61%↑

ABT

125.76

-0.34%↓

LLY

965.93

+4.72%↑

JNJ

187.89

+0.86%↑

UNH

321.52

-0.8%↓

NVS

127.05

+0.61%↑

ABT

125.76

-0.34%↓

LLY

965.93

+4.72%↑

JNJ

187.89

+0.86%↑

UNH

321.52

-0.8%↓

NVS

127.05

+0.61%↑

ABT

125.76

-0.34%↓

LLY

965.93

+4.72%↑

JNJ

187.89

+0.86%↑

UNH

321.52

-0.8%↓

NVS

127.05

+0.61%↑

ABT

125.76

-0.34%↓

LLY

965.93

+4.72%↑

JNJ

187.89

+0.86%↑

UNH

321.52

-0.8%↓

NVS

127.05

+0.61%↑

ABT

125.76

-0.34%↓

Search

PerkinElmer Inc

Fermé

SecteurSoins de santé

0

Résumé

Variation du prix de l'action

24h

Actuel

Min

Max

Chiffres clés

By Trading Economics

Revenu

-8.6M

47M

Ventes

-21M

699M

P/E

Moyenne du Secteur

47.923

77.256

BPA

1.18

Rendement du dividende

0.3

Marge bénéficiaire

6.675

Employés

11,000

EBITDA

-14M

181M

Recommandations

By TipRanks

Recommandations

Achat

Prévisions sur 12 Mois

+22.38% upside

Dividendes

By Dow Jones

Rendement du dividende

Moyenne du Secteur

0.30%

2.33%

Date du Prochain Détachement de Dividende

16 janv. 2026

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

-486M

11B

Ouverture précédente

0

Clôture précédente

0

Sentiment de l'Actualité

By Acuity

32%

68%

96 / 374 Classement par Healthcare

PerkinElmer Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

10 nov. 2025, 22:17 UTC

Résultats

Commonwealth Bank Posts Flat 1Q Profit Despite Margin Pressure -- Update

10 nov. 2025, 21:48 UTC

Résultats

Commonwealth Bank Posts Flat 1Q Profit Despite Margin Pressure

10 nov. 2025, 23:44 UTC

Market Talk

Gold Edges Higher on Signs of Possible End to U.S. Govt Shutdown -- Market Talk

10 nov. 2025, 23:43 UTC

Market Talk

Nikkei May Rise on Weaker Yen, Earnings Hopes -- Market Talk

10 nov. 2025, 22:20 UTC

Acquisitions, Fusions, Rachats

Paramount Stock Climbs as Forecast Beats Estimates -- Barrons.com

10 nov. 2025, 21:50 UTC

Market Talk
Résultats

Basic Materials Roundup: Market Talk

10 nov. 2025, 21:50 UTC

Market Talk
Acquisitions, Fusions, Rachats

Health Care Roundup: Market Talk

10 nov. 2025, 21:49 UTC

Acquisitions, Fusions, Rachats

Paramount Stock Climbs as Forecast Beats Estimates -- Barrons.com

10 nov. 2025, 21:45 UTC

Résultats

PepsiCo and 3 Other Defensive Stocks to Ride Out a Vulnerable Market -- Barrons.com

10 nov. 2025, 21:40 UTC

Résultats

Friedman Industries 2Q EPS 32c >FRD

10 nov. 2025, 21:18 UTC

Résultats

Occidental Petroleum 3Q Adj EPS 64c >OXY

10 nov. 2025, 21:17 UTC

Résultats

Occidental Petroleum 3Q EPS 65c >OXY

10 nov. 2025, 21:17 UTC

Résultats

Occidental Petroleum 3Q Rev $6.72B >OXY

10 nov. 2025, 21:16 UTC

Résultats

Occidental Petroleum 3Q EPS 65c >OXY

10 nov. 2025, 21:16 UTC

Résultats

Occidental Petroleum 3Q Adj EPS 64c >OXY

10 nov. 2025, 20:30 UTC

Market Talk

Expected End to U.S. Government Shutdown Helps Lift Crude -- Market Talk

10 nov. 2025, 20:24 UTC

Market Talk

Hopes For New Government Data Lift Gold -- Market Talk

10 nov. 2025, 20:08 UTC

Market Talk

U.S. Natural Gas Settles Higher As Colder Weather Arrives -- Market Talk

10 nov. 2025, 19:49 UTC

Market Talk

Mexican Industrial Production Seen Soft in September -- Market Talk

10 nov. 2025, 19:43 UTC

Résultats
Acquisitions, Fusions, Rachats

Paramount Earnings Come Amid Warner Bros Merger Reports -- Barrons.com

10 nov. 2025, 19:16 UTC

Résultats

Charles Schwab's CEO Is Worried About Prediction Markets. What He Told Thousands of Financial Advisors. -- Barrons.com

10 nov. 2025, 17:58 UTC

Acquisitions, Fusions, Rachats

Eli Lilly Stock on Pace for a New High. The Zepbound Maker Just Got a Big Upgrade. -- Barrons.com

10 nov. 2025, 17:56 UTC

Market Talk

Oil Futures Edge Up in Rangebound Trade -- Market Talk

10 nov. 2025, 17:32 UTC

Résultats

Barrick Looking to Reset Safety Culture Following Fatalities -- Interview

10 nov. 2025, 17:30 UTC

Résultats

Barrick Continues Efforts to Free Workers Jailed in Mali -- Interview

10 nov. 2025, 17:20 UTC

Market Talk
Résultats

Basic Materials Roundup: Market Talk

10 nov. 2025, 17:20 UTC

Market Talk
Acquisitions, Fusions, Rachats

Health Care Roundup: Market Talk

10 nov. 2025, 17:00 UTC

Résultats

Barrick Looks to Get Handle On North American Operations, Find Growth -- Interview

10 nov. 2025, 17:00 UTC

Résultats

Barrick Expects Strong Cash Flows Ahead With Commodity Prices at Current Levels, CFO Says in Interview

10 nov. 2025, 17:00 UTC

Résultats

Barrick Conducting Bottom-Up Review of Nevada Ops, Looking for Growth Opportunities

Comparaison

Variation de prix

PerkinElmer Inc prévision

Objectif de Prix

By TipRanks

22.38% hausse

Prévisions sur 12 Mois

Moyen 111.1 USD  22.38%

Haut 125 USD

Bas 100 USD

Basé sur 11 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat

11 ratings

8

Achat

3

Maintien

0

Vente

Sentiment

By Acuity

96 / 374Classement par Soins de santé

Sentiment de l'Actualité

Indications Haussières

Volatilité

Inférieur à la moyenne

Changement du Volume d'Actualités (RCV)

Supérieur à la moyenne

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos PerkinElmer Inc

Revvity, Inc. provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. The Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and services. Its Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used for testing and screening genetic abnormalities, disorders, and diseases, including down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. This segment also develops technologies that enable and support genomic workflows using protein coupled receptor and next-generation DNA sequencing for applications in oncology, immunodiagnostics, and drug discovery. It serves pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies under the AutoDELFIA, BACS-on-Beads, BIOCHIPs, Bioo Scientific,BoBs , chemagic, Chitas, DELFIA, DELFIA Xpress, DOPlify, EONIS, EUROArray, EUROIMMUN, EUROLabWorkstation, EUROLINE, EUROPattern, Evolution Evoya, explorer, Fontus, Genoglyphix, GSP, Haoyuan, IDS, IDS-i10 IDS-i10T, IDS-iSYS, iLab, iQ, JANUS, LabChip, LifeCycle, LimsLink, Migele, MultiPROBE, NEXTFLEX, NextPrep, Pannoramic, Panthera Puncher, PG-Seq, PGFind PKamp, PreNAT II, Prime, Protein Clear, ProteinEXact, QSigh, QuantiVac, RONIA, Sciclone, SimplicityChrom, Specimen Gate,Superflex, Symbio, T-SPOT, Touch, Twister, Vanadis, VariSpec, ViaCord VICTOR 2D, and Zephyr brand name. The company was formerly known as PerkinElmer, Inc. and changed its name to Revvity, Inc. in April 2023. Revvity, Inc. was founded in 1937 and is headquartered in Waltham, Massachusetts.
help-icon Live chat